Table 2. . Clinical characteristics.
| Category | N (%) |
|---|---|
| Metabolizer status inferred from genotype | |
| – Ultrarapid | 5 (4.9%) |
| – Normal | 53 (52.0%) |
| – Indeterminate | 9 (8.8%) |
| – Reduced/intermediate | 32 (31.3%) |
| – Poor | 3 (2.9%) |
| Genotype status | |
| – Actionable | 40 (39.2%) |
| – Nonactionable | 62 (60.8%) |
| Drug–drug interactions | |
| – Total | 25 (24.5%) |
| – Fluoxetine† | 6 (5.9%) |
| – Buproprion† | 5 (4.9%) |
| – Paroxetine | 5 (4.9%) |
| – Duloxetine† | 10 (9.8%) |
| – Mirabegron | 1 (1.0%) |
| NSAID use | |
| – Total | 67 (65.7%) |
| – Ultrarapid or poor | 5 (62.5%) |
| – Reduced | 22 (68.8%) |
| – Normal/indeterminate | 40 (64.5%) |
†Two drug–drug interactions involved multiple CYP2D6 inhibitors including buproprion with either fluoxetine or duloxetine.
NSAID: Nonsteroidal anti-inflammatory drug.